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Abstract
Prostate cancer (PCa) is typically found as a multifocal disease suggesting the potential for molecular defects within
the morphologically normal tissue. The frequency and spatial extent of DNA methylation changes encompassing a
potential field defect are unknown. A comparison of non–tumor-associated (NTA) prostate to histologically indistin-
guishable tumor-associated (TA) prostate tissues detected a distinct profile of DNA methylation alterations (0.2%)
using genome-wide DNA arrays based on the Encyclopedia of DNA Elements 18 sequence that tile both gene-rich
and poor regions. Hypomethylation (87%) occurred more frequently than hypermethylation (13%). Several of the
most significantly altered loci (CAV1, EVX1,MCF2L, and FGF1) were then used as probes to map the extent of these
DNA methylation changes in normal tissues from prostates containing cancer. In TA tissues, the extent of methyl-
ation was similar both adjacent (2 mm) and at a distance (>1 cm) from tumor foci. These loci were also able to
distinguish NTA from TA tissues in a validation set of patient samples. These mapping studies indicate that a spa-
tially widespread epigenetic defect occurs in the peripheral prostate tissues of men who have PCa that may be
useful in the detection of this disease.
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Introduction
“Field cancerization” and “field defect” were terms first used in head
and neck tumors to describe an increased frequency of cancer develop-
ment found outside the visible boundaries of the primary tumor [1]. In
the modern era, this definition has been refined to include genetically
or epigenetically compromised cells identified in histologically normal
appearing tissues. A field defect has been identified in gastric, colorectal,
bladder, and esophageal cancers [2–4]. Epigenetic alterations limited
solely to the immediate peritumor environment suggest a response of
the surrounding tissue to the primary cancer. Single-gene epigenetic
studies have identified these changes in a subset of specimens adjacent
to the primary prostate cancers (PCa) [5–7]. Greater controversy exists
whether widespread epigenetic alterations arise within the susceptible
peripheral zone of the prostate that might underlie the regional multi-
focality at diagnosis, as well as the increased incidence with aging [8].
PCa development and progression are driven by the interplay of
genetic and epigenetic changes [9]. One important epigenetic process
is the reversible methylation of cytosine at CpG dinucleotides, a
sequence underrepresented in the genome except at CpG islands
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[10]. DNA hypermethylation at gene promoters leads to gene silencing
and has been observed in preneoplastic lesions and cancers [11,12]. A
decrease in global methylation is a signature of neoplastic processes
and a predisposition to chromosomal instability and cancer [13,14].
Demethylation of LINE-1 elements in normal colonicmucosa in patients
with multiple colon cancers has recently suggested a role for demethyla-
tion in cancer predisposition associated with a field defect [4].
Herein, we used an immunocapture approach to enrich methyl-
ated DNA and combined this with DNA microarrays based on the
Encyclopedia of DNA Elements (ENCODE) 18 sequence that query
functional elements throughout gene regions and are not focused
solely on CpG island promoter regions. We then used these loci to
evaluate the extent of the field defect in histologically normal tissues
from men with PCa. Our data support a spatially widespread change
in DNA methylation throughout the peripheral prostate at multiple
loci that has implications for the development of the disease as well
as clinical treatment.
Materials and Methods
Tissue Samples and Histopathology
Samples termed non–tumor-associated (NTA; mean, 63; range, 55–
81 years) were obtained from organ donation or cystoprostatectomy
and had extensive histologic evaluation to rule out associated PCa.
Tumor-associated (TA; mean, 61; range, 57–64 years) prostate tissues
were obtained from patients who underwent radical prostatectomy
for PCa. The clinical-pathologic characteristics for all samples used
in these studies are presented (Table W1). A separate validation group
consisting of 12 NTA (mean, 60; range, 55–70 years) and 11 TA
(mean, 57; range, 51–67 years) samples were evaluated using quanti-
tative pyrosequencing.
To define the relationship of methylation to tumor foci, histologic
sections containing both cancer and normal regions were generated
from 26 (mean, 58; range, 44–69 years) radical prostatectomy speci-
mens. Microdissection was performed to obtain tumor (T) and normal
tissue adjacent (2 mm) to tumor foci (TAA) and at a greater distance
(10 mm, TAD) as described [15]. Additional histopathologic criteria
for the TA and NTA samples included similar epithelial-to-stromal
ratios and lack of inflammation. Prostate specimens were confirmed
to have no tumor by both hematoxylin and eosin (H&E) staining in
three dimensions using step sectioning and α-methylacyl-CoA expres-
sion. For AMACR analysis, RNA was extracted using an RNeasy Mini
Kit (Qiagen, Valencia, CA), and 300 ng of RNAwere reverse transcribed
with Ominscript. Quantitative real-time polymerase chain reaction
(PCR) for total AMACR was performed using primer sequences, as re-
ported [16]. This study was approved by Institutional Review Boards at
the University of Wisconsin-Madison and the University of Pittsburgh.
DNA Methylation Microarrays
Genomic DNA was isolated using the DNeasy Blood and Tissue Kit
(Qiagen). Roche NimbleGen ENCODE HG18 DNA methylation
arrays were used. These arrays contain 385,000 50mer oligonucleotides
(probes) that cover elements such as protein-coding genes, transcription
units, protein binding sites, conserved DNA elements, chromatin
assembly and modification features, and single-nucleotide polymor-
phisms. Notably, the probes are placed at 60-bp intervals to include
both CpG and non-CpG islands within gene bodies, promoters, as well
as intergenic regions (UCSC Genome browser, http://genome.ucsc.
edu/ENCODE/encode.hg18.html). All chromosomes are represented
on the arrays with the exception of 3 and 17.
Sample preparation for the microarray was performed follow-
ing the manufacturer’s protocol as previously detailed [11]. Briefly,
2 to 6 μg of high-quality genomic DNA was digested with MseI
(New England Biolabs, Ipswich, MA) to produce 200 to 1000 bp
fragments (keeping CpG islands intact) and then heat denatured
to form single strands. Methylated DNA fragments were immuno-
precipitated (IP) with 1 μg of antibody against 5-methylcytidine
(Abcam, Cambridge, MA) and captured with agarose beads. The
DNA/antibody/bead mixture was digested with Proteinase K and
purified with phenol-chloroform. Enrichment of the methylated
IP DNA was validated with PCR primers for the H19-ICR specific
for methylated DNA and FLJ25439 specific for unmethylated regions
as described [17]. The labeling of IP and inputDNA,microarray hybrid-
ization, and scanning were performed by NimbleGen Laboratories
(Reykjavik, Iceland) as described [18].Data were extracted from scanned
images by using NimbleScan 2.4 extraction software (NimbleGen
Systems, Inc, Madison, WI). The samples were assayed in duplicate.
Quantitative Pyrosequencing
Sodium bisulfite modification of genomic DNA was performed
using the EpiTect Bisulfite Kit (Qiagen). Bisulfite-modified DNA
was then amplified using PCR in preparation for pyrosequencing,
with either the forward or reverse primer biotinylated [19]. All
PCR and sequence primers for pyrosequencing were designed using
PyroMark Assay Design 2.0 (Qiagen), and primer sequences are
listed in Table W2A. The biotinylated PCR products were captured
with streptavidin sepharose beads, denatured to single strand, and
annealed to the sequencing primer for the pyrosequencing assay. SssI
methylase-treated bisulfite-converted DNA from human prostate
epithelial cell and PPC1 were used as positive controls, and water
substituted for DNA was used as a negative control. Methylation
was quantified with the PyroMark MD Pyrosequencing System
(Qiagen) within the linear range of the assay. All samples were ana-
lyzed by three independent experiments in duplicate.
Analysis of Methylation and Gene Expression
DNA and RNA were obtained from normal human prostate epi-
thelial cells primary cultured from five patients and four human PCa
cell lines (PC3, PPC1, Du145, and LNCaP). DNA methylation was
evaluated by pyrosequencing as described above. Gene expression
was measured by reverse transcription–quantitative PCR (RT-
QPCR) using a Bio-Rad CFX 96 Real-Time PCR System and SYBR
Green PCR Master Mix (Applied Biosystems, Grand Island, NY) as
described. Primer sequences are listed in Table W2B. mRNA levels
of each gene were normalized to β-actin as ΔCT. Experiments were
performed in duplicate in three independent experiments; a t test was
used to compare the PCa cells to the normal prostate epithelial cells.
Data Analysis
Scaled log2 ratio gene-finding format (GFF) file and P value GFF
files provided by NimbleGen Systems, Inc were used for microarray
analysis. The scaled log2 ratio is the ratio of the test sample to the
input signal when co-hybridized to the array. Scaling was performed
by subtracting the biweight mean for all array features. From the
scaled log2 ratio data, a fixed-length window was placed around each
consecutive probe and the one-sided Kolmogorov-Smirnov test was
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applied to determine whether the probes had a significantly more
positive distribution of intensity log ratios than those in the rest of
array. The resulting score for each probe was the −log10 P value.
The probe IDs were first chosen on the basis of a −log10[P] value that
ranged from 2 to 10 resulting in around 1000 probes on each chro-
mosome and 18,101 probes in total. A statistical analysis comparing
the log2 ratios between the NTA and TA groups for the probes was
then determined using a t test (P < .05). We used the more appropri-
ate standard t test or the Satterthwaite approximation t test, depend-
ing on testing for equal variances when evaluating these data.
Significantly changed probes were clustered by Java MultiExperiment
View (MEV 4.6.2) with unsupervised hierarchical clustering [20]. For
quantitative pyrosequencing, the methylation at each CpG site was
expressed as a percentage. A two-tailed t test was used to test for differ-
ences between groups; P < .05 was considered statistically significant.
Results
Distinct Patterns of DNA Methylation Define TA from
NTA Prostate Tissues
To identify probes, we used 385,000 locus arrays based on the
ENCODE18 sequences that densely tile a series of biologically sig-
nificant regions in ∼1% of the human genome. These arrays query
Figure 1. DNA methylation analysis using ENCODE18-based arrays of TA and NTA prostate tissues. (A) Verification of the IP for meth-
ylated DNA. Single-gene PCR was applied to both total genomic (Input) DNA and IP DNA before array analysis as described in Materials
and Methods section. The H19 ICR served as a positive control for methylation and FLJ 25439 as a demethylation control. The IP shows
lower demethylated levels. (B) Schema of methods. Genes aberrantly methylated in TA compared to NTA were identified by using an
intensity cutoff (−log10[P] = 2–10), then a t test was used to compare the log2 ratios between groups. For further validation, statistical
significance was used to rank the probes. (C) Genome-wide distribution of DNA methylation array differences at 385,000 loci in histo-
logically normal TA prostate tissues compared to NTA tissues. Significant differences in methylation between TA and NTA prostate
tissues were generated using a cutoff of probe score of−log10[P] = 2–10 and t test between two groups (P< .05). A total of 615 probes
were differentially methylated in TA tissues with 537 demonstrating hypomethylation and 78 hypermethylation. The percentage (axis) is
the significantly altered probe number versus the total probe number analyzed for each chromosome. Chromosomes 15 and 20 were
differentially methylated to a greater extent than other chromosomes. (D) Heat map of significant DNA methylation array changes using
unsupervised hierarchical clustering. Using more stringent criteria (t test, P < .01), 86 probes are shown comparing sets of NTA (left) to
TA (right) and hierarchically ordered from top to bottom by relatively hypermethylation to hypomethylation. Green indicates relative
hypomethylation, whereas the red shaded areas demonstrate hypermethylation of the TA set.
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functional elements throughout gene regions and are not focused
solely on CpG island promoter regions. DNA was initially prepared
in duplicate from four TA and five NTA prostate specimens, restriction
digested, and enriched for methylated DNA by IP with an antibody
against 5-methylcytidine, as described [11]. Peripheral zone prostate
tissues were used for all of these studies as PCa demonstrates a predi-
lection for this region.
To validate the IP, single-gene PCR was applied to confirm an
enrichment of methylation in IP DNA compared to total genomic
DNA (Input; Figure 1A). Total IP DNA and Input DNA were labeled
with Cy5 and Cy3 dye, respectively, and then co-hybridized to the
array (Figure 1B) [17]. There were 18,101 significant loci identified
that were then statistically compared between TA and NTA tissue
groups [21,22]. This generated 615 probes (0.16% of total) that were
differentially methylated in TA tissues, of which 537 (87%) were
hypomethylated and 78 (13%) were hypermethylated (P < .05;
Figure 1C ). Microarray data are available at http://www.ncbi.nlm.
nih.gov/geo (Accession No. GSE38982).
Chromosome 15 demonstrated the greatest number of significantly
differentially methylated probes (1.1%) in TA tissues, followed by
chromosome 20 (0.9%). Across genomic regions, specific peaks were
identified and defined as regions containing greater than two probes
within a 500-bp length (TableW3A). From these results, we concluded
that altered methylation between TA and NTA tissues occurs infre-
quently when using ENCODE-based genome arrays. Furthermore,
arrays that query areas beyond promoter CpG islands reveal that
Figure 1. (continued).
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hypomethylation was more prevalent than increased methylation in
tissues associated with tumors.
Identification of Probes for Analyzing the Field Defect in
Prostate Specimens
To limit the number of loci for further study, more stringent
statistical parameters (P < .01) were applied identifying 86 probes
(Figure 1B). These probes were subjected to unsupervised hier-
archical clustering using TMEV software to pictorially generate
a heat map of methylation distinguishing TA from NTA prostate
tissues (Figure 1D). Among these loci, 68 were hypomethylated and 18
were hypermethylated in TA tissues. Of these, 38 probes were not
closely related to genes (Table W3B), and 48 were within 35 genes
(Table 1). Loci associated with genes were primarily located within
introns (78%) and were distant from transcription start sites.
Of the 48 gene-related probes (representing 35 genes), we evalu-
ated 20 loci that demonstrated the most significant methylation
changes on our arrays (Table 1). This included both hypermethy-
lated and hypomethylated probes. In a separate set of 11 TA and
12 NTA prostate specimens, quantitative pyrosequencing was em-
ployed to validate these DNA methylation differences [19]. Because
of technical reasons (mainly high CG density and mispriming; both
limitations of pyrosequencing), we were unable to generate functional
primers that covered 11 loci. NCR2, WNT2, and three others were
not initially validated, although NCR2 and WNT2 were significantly
altered in a high-grade disease subset (see below). We validated
CAV1, EVX1, and MCF2L (hypermethylated) and FGF1 (hypo-
methylated) in this tissue set (Figure 2A). The location of these four
loci relative to gene structure is demonstrated in Figure 2B. These re-
gions were downstream from the transcription start site and included
both exonic and intronic regions making them less likely to alter gene
Table 1. Gene-related Loci Ranked by Significance.
Gene Gene Name Accession No. Location Hypermethylation or
Hypomethylation
Distance to
TSS
CpG
Island
Gene
Body
Exon/
Intron
MCF2L* Cell line derived transforming sequence-like NM_024979 Chr13: 112,704,068–112,792,498 Hyper +117331 Y Y Intron
RAB11FIP3* RAB11 family interacting protein 3 NM_014700 Chr16: 415,668–512,482 Hypo +31178 Y Y Intron
CNOT3 CCR4-NOT transcription complex 3 BC016474 Chr19: 59,333,294–59,351,230 Hyper +10789 Y Y Exon
NCR2* Natural cytotoxicity triggering receptor 2 AJ010100 Chr6: 41,411,566–41,426,579 Hypo +14989 Y Y Exon
IER5L Immediate early response 5-like NM_203434 Chr9: 130,978,873–131,012,683 Hypo −28327 N N –
SERF2 Small EDRK-rich factor 2 BC015491 Chr15: 41,871,834–41,873,536 Hyper +15217 Y Y Exon
FRMD5 FERM domain containing 5 NM_032892 Chr15: 41,952,764–42,274,683 Hypo +311563 N Y Intron
MCF2L Cell line derived transforming sequence-like NM_024979 Chr13: 112,704,068–112,792,498 Hyper +65503 N Y Intron
FAM83C Family with sequence similarity 83 C NM_178468 Chr20: 33,336,947–33,343,639 Hyper +189 Y Y Exon
FRMD5 FERM domain containing 5 NM_032892 Chr15: 41,952,764–42,274,683 Hypo +321825 N N –
DEPDC5 DEP domain containing 5 AJ698951 Chr22: 30,480,852–30,632,599 Hypo +151926 N Y Intron
EVX1* Even-skipped homeobox 1 NM_001989 Chr7: 27,248,945–27,252,717 Hyper +1419 Y Y Intron
MAP1A Microtubule-associated protein 1A NM_002373 Chr15: 41,597,132–41,611,110 Hypo +4246 Y Y Exon
FGF1* Fibroblast growth factor 1 NM_000800 Chr5: 141,953,305–142,045,812 Hypo +29175 Y Y Intron
SYN3 Synapsin III NM_003490 Chr22: 31,238,539–31,732,683 Hypo +284369 N Y Intron
GRM8 Glutamate receptor, metabotropic 8 NM_000845 Chr7: 125,865,894–126,670,548 Hypo +584116 N Y Intron
SERPINB8 Serpin peptidase inhibitor B8 BC034528 Chr18: 59,788,332–59,804,866 Hyper +374 Y Y Intron
CAV1* Caveolin 1 AF 172085 Chr7: 115,953,642–115,986,904 Hyper +1855 Y Y Exon
WNT2* Wingless-type MMTV integration site BC 078170 Chr7: 116,704,514–116750565 Hypo +19961 Y Y Intron
CEP250* Centrosomal protein AF022655 Chr20: 33,511,231–33,563,123 Hypo +17863 N Y Intron
PI4KCB* Phosphatidylinositol 4-kinase NM_002651 Chr1: 149,531,036–149,565,348 Hypo +11021 N Y Intron
PISD Phosphatetidylserine decarboxylase CR456540 Chr22: 30,345,379–30,388,195 Hypo −13468 N N –
GRM8 Glutamate receptor, metabotropic 8 NM_000845 Chr7: 125,865,894–126,670,548 Hyper +398576 N Y Intron
SPAG4 Sperm associated antigen 4 NM_003116 Chr20: 33,667,222–33,672,379 Hyper +1793 Y Y Intron
NCR2 Natural cytotoxicity triggering receptor 2 AJ010100 Chr6: 41,411,566–41,426,579 Hypo +15264 Y N –
FRMD5 FERM domain containing 5 NM_032892 Chr15: 41,952,764–42,274,683 Hypo +293027 Y Y Intron
NRXN2 Neurexin 2 NM_138734 Chr11: 64,130,221–64,167,363 Hypo +81441 N Y Intron
ACCN4 Amiloride-sensitive cation channel 4 NM_182847 Chr2: 220,087,295–220,111.738 Hypo +3525 Y Y Intron
SERPINB2 Serpin peptidase inhibitor, B2 NM_002575 Chr18: 59,705,921–59,722,100 Hypo +2820 N Y Intron
CEP250 Centrosomal protein AF022655 Chr20: 33,511,231–33,563,123 Hypo +18228 N Y Intron
FRMD5 FERM domain containing 5 NM_032892 Chr15: 41,952,764–42,274,683 Hyper +314296 N Y Intron
FER1L4 Fer-1–like 4 AL833764 Chr20: 33,609,920–33,651,008 Hypo +46003 N Y Intron
ERGIC3 ERGIC and golgi 3 AF116614 Chr20: 33,593,290–33,608,818 Hypo +9863 Y Y Intron
TRPM8 Transient receptor potential cation channel NM_024080 Chr2: 234,490,781–234,592,905 Hypo +8786 N Y Intron
TFEB Transcription factor EB NM_007162 Chr6: 41,759,693–41,810,766 Hypo +33939 Y Y Intron
SEPT8 Septin AF440762 Chr5: 132,114,415–132,140,966 Hypo +9050 Y Y Intron
EXT1 Exostoses 1 BC001174 Chr8: 118,880,782–119,192,632 Hypo +156580 N Y Intron
GDF5 Growth differentiation factor 5 NM_000557 Chr20: 33,484,562–33,489,441 Hypo +2409 N Y Intron
SEPT8 Septin AF440762 Chr5: 132,114,415–132,140,966 Hypo +3430 Y Y Intron
NRXN2 Neurexin 2 NM_138734 Chr11: 64,130,221–64,167,363 Hypo +110421 Y Y Intron
TP53BP1 Tumor protein p53 binding protein 1 NM_005657 Chr15: 41,486,698–41,590,028 Hypo +15672 N Y Intron
F7 Coagulation factor VII NM_019616 Chr13: 112,808,105–112,822,346 Hypo +14087 Y Y Exon
LILRA5 Leukocyte immunoglobulin-like receptor A5 NM_181985 Chr19: 59,510,164–59,516,221 Hypo +2824 N Y Intron
DECR2 2,4-dienoyl CoA reductase 2 AK128012 Chr16: 391,893–402,371 Hyper +9490 Y Y Intron
FRMD5 FERM domain containing 5 NM_032892 Chr15: 41,952,764–42,274,683 Hyper +314576 N Y Intron
PI4KCB Phosphatidylinositol 4-kinase NM_002651 Chr1: 149,531,036–149,565,348 Hypo +20522 N Y Intron
NCR2 Natural cytotoxicity triggering receptor 2 AJ010100 Chr6: 41,411,566–41,426,579 Hypo +15109 Y N –
MAP1A Microtubule-associated protein 1A NM_002373 Chr15: 41,597,132–41,611,110 Hypo +5906 Y Y Exon
*Probes subjected to validation using quantitative pyrosequencing. Of the initial 20 loci listed, 11 were not able to be assessed due to technical limitations regarding probe design and performance.
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expression. To evaluate this issue, we performed a correlation analysis
for these four loci examining methylation and gene expression in a se-
ries of normal prostate epithelial cells (five) and PCa cell lines (four).
Changes in methylation did not correlate with altered transcript ex-
pression from these four associated genes (FigureW2). The above data
validated these four primer sets as tools marking an epigenetic field
defect present in men with associated PCa that were then used in
subsequent mapping experiments.
Identification of a Widespread Methylation Field Defect in the
Peripheral Prostate
We then used these probes to test whether tissues adjacent to PCa
tumor foci are preferentially altered, suggesting only an immediate peri-
tumor response, or whether aberrant methylation occurs at a distance
from the tumor indicating a more widespread field defect. The extent of
the field defect was assessed using four differentially methylated markers
in 26 additional histologically normal tissues from men with cancer.
Clinical and pathologic information is presented (Table W1). We
dissected normal tissues 2 mm adjacent (TAA) and compared these
to tissue more than 10 mm distant (TAD) from the main tumor focus
for each of these 26 specimens (Figure 3A). H&E staining of step
sections was used to exclude contamination by tumor cells, significant
inflammation, and the presence of high-grade prostatic intraepithelial
neoplasia (PIN), a putative cancer precursor [23]. AMACR expression,
a PCa marker, was determined by QPCR, and samples contaminated
by overt cancer were removed (Figure W1).
When compared to NTA tissues, hypermethylation of probes asso-
ciated with CAV1, EVX1, andMCF2L and hypomethylation of FGF1
demonstrated significant changes in both adjacent (TAA), as well as
distant tissues (Figure 3B). Results for each CpG tested are listed in
Table W4. We noted no significant difference in the extent of meth-
ylation seen at different distances from the tumor using these
unbiased probes. We also evaluated methylation in the associated
tumor (T) for each sample. The methylation change representing
the field defect was also present in the tumor samples at three loci.
At FGF1, the tumor did not demonstrate hypomethylation similar
Figure 2. Validation of loci identified by DNAmethylation array in additional prostate tissues using quantitative pyrosequencing. (A) Analysis
of methylation was performed using quantitative pyrosequencing as described in Materials and Methods section. An additional validation
set of NTA tissues (12) was compared to TA tissues (11). All loci shown were significantly altered in TA when compared to NTA samples
(P< .05). (B) Location of selected loci within genes that were analyzed by quantitative pyrosequencing. Exon and intron boundaries are
shown, as well as the transcription start site. The genome-wide analysis resulted in loci that were not typically located in promoter CpG
islands. Tick marks represent CG sites analyzed.
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to the TA tissue, suggesting that these defects are not always enriched
for in the associated tumors. In summary, similar methylation extent
in both adjacent and distant tissues indicates that the epigenetic field
defect in the prostate is spatially widespread and not localized solely to
the immediate peritumor environment.
We also performed a subset analysis on TA tissues looking at these
changes in intermediate (Gleason 5–7) or high-grade (Gleason 8–10)
cancers. Two loci, NCR2 and WNT2, that were not significantly
altered when all tissue grades were examined were found to be sig-
nificantly altered in the high-grade but not intermediate-grade sub-
set (Figure 4A). The location of NCR2 and WNT2 relative to gene
structure is demonstrated in Figure 4B. Other loci did not distin-
guish between the field defect associated with high- or low-grade dis-
ease. These data suggest that distinct field methylation alterations
may be solely associated with the presence of high-grade cancer.
Discussion
Research has led to a proposal that a field defect may underlie the
development of multifocal cancer [1]. Initial efforts in characterizing
Figure 3. Analysis of extent of field defect in prostatectomy samples using identified probes. (A) Schematic showing prostate tumor (T)
and adjacent (TAA) and distant (TAD) normal tissue dissection as well as NTA specimens. Radical prostatectomy samples containing
tumor foci were sectioned and samples dissected for subsequent analyses. Adjacent and distant TA tissues did not contain histologic
cancer. Samples were assessed three-dimensionally using step sectioning. (B) Analysis of methylation at differentially methylated loci in
above dissected prostate tissues and NTA prostate tissues using quantitative pyrosequencing. Methylation analyses for CAV1, EVX1,
MCF2L, and FGF1 were significantly different when comparing T, TAA, or TAD to NTA (*P < .05). No significant erosion in methylation
with increasing distances from the primary tumor was observed when TAA was compared to TAD. Technical replicates obtained from
independent PCR reactions showed average SDs of 2.4% for CAV1, 1.5% for EVX1, 1.6% for MCF2L, and 2.1% for FGF1, respectively.
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this process focused on genetic alterations [24,25]. More recently,
epigenetic changes have been proposed as an etiology [26,27]. In
the current study, we used high-resolution genome-wide arrays that
cover a range of biologically significant regions (not limited to pro-
moter regions) to identify significant changes in DNA methylation
that occur within histologically normal tissues associated with PCa.
We validated several of these loci and used them as probes to dem-
onstrate for the first time that methylation changes are spatially wide-
spread and not restricted to the immediate peritumor environment as
previously thought [2,4,15]. Finally, these methylation alterations
permit a clear distinction between TA and NTA prostate tissues.
To date, epigenetic profiling of TA histologically normal tissues
has not been performed in the prostate. Our genome-wide assess-
ment of specific loci demonstrates that hypomethylation was seen
more commonly than hypermethylation in TA prostate tissues. This
surprising finding may be a result of using arrays that do not solely
examine promoter CpG islands but densely assess gene-enriched
regions, including intergenic regions, of the genome. The use of these
arrays also explains the relatively low frequency of methylation
changes (0.2%) found compared to studies in other cancers using
CpG promoter arrays [28]. Hypomethylation was recently found at
LINE-1 sequences in normal colonic mucosa of patients with multi-
ple colon cancers, suggesting that demethylation may underlie the
field defect found in these patients [4]. These findings were also
increased with aging, and the authors proposed a “wear and tear”
model to explain the propensity of colon cancer with aging [4]. In
the prostate, DNA hypomethylation may be found in PIN [29], a
cancer precursor. Our data that widespread hypomethylation occurs
in the prostate field defect extend these findings and lead to specula-
tion that epigenetic alterations in TA tissues may possibly precede the
histologic changes of PIN and cancer.
A debate exists regarding whether the peripheral prostate may
undergo widespread methylation changes similar to bladder cancer, a
disease also characterized by multifocality and recurrence [27]. In
bladder, there was no dependence on distance from the primary tumor.
Previously, methylation studies using single genes GSTP1, RASSF1A,
APC, and RARβ2 altered in PCa identified methylation changes in a
subset of specimens only adjacent to the primary tumor [5–7]. This
suggested that methylation alterations were limited solely to the imme-
diate peritumor environment in the prostate. In contrast, in the present
epigenomic profiling study, we find that methylation alterations con-
sistently extended even to regions distant (>1 cm) from tumor foci. A
similar widespread field defect was demonstrated during evaluation of
insulin-like growth factor 2 loss of imprinting in peripheral prostate
tissues [15]. Insulin-like growth factor 2 loss of imprinting is an age-
related event in the human prostate that is associated with cancer
formation [30]. This epigenetic association has also been seen in the
colon and predisposes to cancer formation [31]. These data suggest a
more widespread methylation change in the histologically normal
peripheral prostate of men with cancer that we postulate predisposes
the gland to multiple tumor formation with aging. Further research
will be needed to address this hypothesis and how a widespread
methylation field defect might arise, whether due to diet or environ-
mental exposures [32,33].
Our primary goal was to use methylation arrays to define an un-
biased panel of probes with which to evaluate whether a widespread
Figure 4. Analysis demonstrates a relationship between grade and methylation for several tested loci. (A) Quantitative pyrosequencing
was performed on nine loci (Table 1). Prostate tumor (T), adjacent (TAA), and distant (TAD) tissues were divided into high- (Gleason score
of 8–10) and intermediate- (Gleason score of 5–7) grade tissues. Tissues without associated cancer were also evaluated (NTA). NCR2
and WNT2 were found to only be significantly hypomethylated in TA tissues associated with the presence of high-grade cancer when
compared to NTA (P < .05). (B) Location of NCR2 and WNT2 region where the probes are located.
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field defect occurs in PCa. Thus, we used a more limited number of
samples initially and further validated a panel of genes with quanti-
tative pyrosequencing. We found six of nine loci to be validated in
our other tissue sets, indicating a false discovery rate of 33%. To se-
lect loci for validation, we used approaches commonly employed in
gene array studies (e.g., statistical value) [11]. The majority of probes
identified fell within CpG islands [34], but interestingly none fell
into defined gene promoter regions (Table 1). Hypermethylation
within promoters has been linked to decreased gene expression
[35,36], but the function of CpG islands outside these regions re-
mains uncertain. No correlation with expression and methylation
was noted at the majority of these loci when normal and cancer cell
lines were examined (Figure W2). At NCR2 and WNT2, a cor-
relation was seen between increased methylation and expression.
Methylation within the gene bodies has been associated with elevated
gene expression in genome-wide studies [37]. These changes may
reflect alternate promoter usage that could impact expression in a sense
or antisense manner. Alternatively, given the potential for long-range
epigenetic silencing through chromatin looping, we postulate that the
methylation changes identified may herald alterations in nuclear struc-
ture that influence gene expression at distant sites [38].
The current findings suggest a methylation field defect that may
encompass peripheral prostate tissue, the susceptible region of the
gland, even at a distance from the tumor. These findings have several
additional implications. Several of the loci identified in this study
were recently used as a test to successfully identify the presence of
PCa elsewhere in the prostate solely from normal biopsy tissue in
a group of clinical patients with an excellent area under the curve
of 0.79 [39]. An additional finding of several regions that were asso-
ciated only with high-grade cancer might suggest an early marker for
more aggressive PCa. Finally, the assessment of alterations that occur
in PCa have typically compared tumor to “normal” tissues within the
same prostate gland. The current study indicates that histologically
normal tissue from men who have PCa may already contain methyl-
ation abnormalities leading to an underestimation of epigenetic
changes within the tumor.
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Table W1. Clinical and Pathologic Characteristics.
Methylation Array Pyrosequencing
NTA TA NTA TA T, TAA, TAD
Number 5 4 12 11 26
Age (years) 63 (55–81) 61 (57–64) 60 (55–70) 59 (51–67) 58 (44–69)
Tumor volume (%) 6.3 (5–10) 5.1 (1–10) 27.1 (5–80)
Gleason grade
Intermediate 4 11 16
High 10
PSA (ng/ml) 7.7 (4–14) 5.9 (3–14) 6.9 (3–27)
NTA indicates non–tumor-associated normal; PSA, prostate-specific antigen; TA, tumor-associated;
T, tumor; TAA, tumor-associated adjacent; TAD, tumor-associated distant; Gleason grade, inter-
mediate: 3 + 3, 3 + 4; high: 4 + 4, 4 + 5, 5 + 5.
Table W2. Primer Sequences.
(A) Pyrosequencing
CAV1 F—GGGTAATATTTATAAGTTTAATAATAAGGT
R-biotin—TAAAAACTATCCCAACCCTTC
Seq—AAGTTTAATAATAAGGTTATGGTAG
EVX1 F—GGAGGAGAGGAAGTTAGGAGTTTATAAAGGA
R-biotin—CAAATACAACCCAAAACCAAAAACAAT
Seq—GAAGTTACGAGTTTATAAAGGAT
FGF1 F—GGATGGGATAGTGAAGATAAGAGT
R-biotin—TTCAACATACTATCATCTAATCCTTTACAC
Seq—TTTTTTTAAGGTTATGTGATAA
MCF2L F-biotin—GAGTTGAGTTTTATTTTGGGTATTTTGAAG
R—ACCCCCAAATTACTAAACTAATATATTCC
Seq—CAAATTACTAAACTAATATATTCCA
NCR2 F-biotin—GTTGTGGGAGAGTAAGGTTTGGAAATAA
R—CTCATCTCCACCCCCTTCATTTT
Seq—CCCCCTTCATTTTCT
WNT2 F—TTTTGGAGGTATAGGGTAGGAAATAA
R-biotin—AATTCAAAATCATCCAAACCCAAA
Seq—AGGAAATAATTTTTAATTGAATA
(B) QPCR
CAV1 F—AACGATGACGTGGTCAAGATTG
R—TCCAAATGCCGTCAAAACTGT
EVX1 F—AACGCCGAGTACCAGCAC
R—GTCTCGCTCCCTCCGTTC
FGF1 F—GGAAAGGCTGGAGGAGAACC
R—TCTGGCCATAGTGAGTCCGA
MCF2L F—ACCTGTTCCTGCACGAGAAG
R—ACGGCAGCCATGTTTAAGGA
NCR2 F—TTCCCTCTCCCCAGTCTTCT
R—GCATCTCACGGTTAGCGTCT
WNT2 F—TAATATGAACGCCCCTCTCG
R—GCACATTATCGCACATCACC
F indicates forward primer; R, reverse primer; biotin, biotinylated primer; Seq, pyrosequencing primer.
Table W3A. Methylation Peak Locations.
Chromosome Peak No. Start Position End Position
Chr1 1 149471274 149471513
2 149528409 149528518
3 149545855 149546294
4 149623022 149623181
5 149808643 149809297
Chr2 1 220090490 220090769
2 234377845 234378894
Chr4 1 118965488 118965968
Chr5 1 131352045 131352509
2 131353542 131353876
3 131662526 131662635
4 131738235 131738344
5 132044542 132044702
6 132137727 132138031
7 132191345 132191874
8 132192955 132193244
9 142028596 142029130
10 142231413 142231596
Chr6 1 41421472 41421891
2 41426189 41427118
3 41531833 41531948
4 41770751 41770870
5 41799276 41799620
6 41823331 41823725
7 73941136 73941485
Chr7 1 27249867 27250156
2 27329287 27329461
3 89900634 89901018
4 115953729 115954078
5 116053599 116054133
6 116730563 116730672
7 126095419 126095629
Chr8 1 118892676 118892958
2 118981490 118981574
3 119332465 119332799
Chr9 1 130735749 130735968
2 130748357 130749031
3 131036065 131036459
4 131077814 131077910
5 131199253 131199592
Chr11 1 1719582 1720442
2 1892487 1892861
3 2031460 2031576
4 2254238 2254517
5 5400317 5400471
6 5505469 5505573
7 64136767 64137036
8 64140349 64140643
9 64165697 64165796
10 64220022 64220131
11 64223122 64223231
12 116094656 116104386
13 116134115 116134214
14 130699599 130699723
15 130824509 130824633
16 131058349 131058948
Chr13 1 29419683 29419977
2 29488197 29488651
3 29495438 29495592
4 112366570 112366660
Chr14 1 53173801 53173890
2 98498457 98498806
3 98826247 98826826
4 98862101 98870359
5 98917892 98918201
Chr15 1 41601343 41601642
2 41602618 41603052
3 41879980 41880329
4 41897310 41897496
5 41952848 41953161
6 41960097 41960426
7 41991646 41991872
Chr16 1 45572 46086
2 446846 467671
Table W3A. (continued )
Chromosome Peak No. Start Position End Position
Chr18 1 24184165 24184600
2 59588293 59588522
3 59788616 59788830
4 59821299 59821403
Chr19 1 59095365 59095885
2 59322652 59323121
3 59334890 59335125
4 59343796 59344085
5 59348570 59358710
6 59448338 59448582
7 59513349 59513583
8 59523587 59523836
9 59558462 59558551
10 59743846 59744908
11 59745418 59745535
Chr20 1 33524449 33524913
2 33552909 33553188
3 33564800 33565739
4 33597765 33597993
5 33603054 33603485
6 33634685 33634899
7 33668975 33669309
8 33677193 33677370
9 33682853 33682942
Chr21 1 33176986 33177105
2 34182551 34182660
3 34278040 34278284
4 34281522 34282041
5 39265487 39265596
6 39409185 39409589
Chr22 1 30438680 30438779
2 30631862 30632071
3 30640190 30640309
4 30699213 30699682
5 31192667 31192831
6 31254314 31254964
7 31286769 31286943
8 31407471 31408425
Table W3B. Methylated Loci Not Related to Genes.
Location Hypomethylation or Hypermethylation
Chr1: 149622432–149622488 Hypo
Chr1: 149623022–149623071 Hypo
Chr1: 149709551–149709600 Hypo
Chr2: 234378610–234378659 Hypo
Chr4: 118792613–118792662 Hyper
Chr5: 131617349–131617398 Hypo
Chr5: 132193075–132193124 Hypo
Chr6: 41823506–41823556 Hypo
Chr6: 41823631–41823687 Hypo
Chr7: 27241669–27241718 Hyper
Chr7: 289900969–89901018 Hypo
Chr9: 131077859–131077910 Hypo
Chr11: 1754652–1754701 Hypo
Chr11: 116103872–116103921 Hypo
Chr11: 116103927–116103976 Hypo
Chr11: 116104277–116104326 Hypo
Chr11: 130699674–130699723 Hypo
Chr13: 29419753–29419802 Hypo
Chr13: 29495438–29495487 Hypo
Chr13: 112589940–112589989 Hyper
Chr14: 53173801–53173850 Hypo
Chr14: 98826247–98826296 Hypo
Chr14: 98862411–98862460 Hypo
Chr15: 41878131–41878180 Hyper
Chr15: 41879095–41879145 Hypo
Chr16: 46697–46746 Hypo
Chr18: 24020017–24020072 Hypo
Chr18: 24184165–24184221 Hypo
Chr18: 59906729–59906778 Hypo
Chr20: 33564800–33564852 Hypo
Chr21: 32827756–32827805 Hypo
Chr21: 32869578–32869627 Hyper
Chr21: 33434061–33434110 Hypo
Chr21: 34265892–34265949 Hypo
Chr21: 34281627–34281676 Hypo
Chr21: 34281992–34282041 Hypo
Chr21: 39409540–39409589 Hypo
Chr22: 31056173–31056222 Hypo
Table W4. Methylation Percentage of All Analyzed CpGs for Each Gene in Microdissected
Prostate Specimens.
NTA TAA TAD
CAV1
4.5* 8.8† 9.6†
14.6 22.4† 21.3†
17.8 27.7† 25.8†
13.8 24.3† 23.0†
15.3 25.0† 21.9†
14.9 27.2† 26.4†
18.9 28.0† 26.0
8.3 15.4† 14.7†
15.8 22.7 19.5
17.9 26.7† 28.6†
EVX1
30.5 38.8† 32.6
28.2 36.9† 29.9
22.7 30.8† 27.8†
50.4 55.4 48.3
46.5 51.7 47.2
36.7 44.8† 40.6†
MCF2L
80.2 85.2† 85.3†
77.0 85.3† 85.1
96.3 97.4† 96.5
84.8 82.1 80.7†
79.9 86.1 87.5†
FGF1
80.4 70.7† 70.8†
71.7 60.7† 59.8†
71.2 60.2† 60.9†
81.1 72.9† 71.1†
‡NCR2
54.3 50.8 52.1
74.7 68.6† 70.7
WNT2
95.4 89.8† 89.8†
94.9 91.0† 91.5†
100 99.5 100
*CG sites listed in order.
†P < .05.
‡High-grade tumor only.
Figure W1. AMACR expression in NTA, T, TAA, and TAD prostate
tissues. AMACR is a specific marker expressed by PCa and prema-
lignant lesions. AMACR expression was assayed using RT-QPCR
and the data are shown as ΔCT. On the basis of the above data,
two NTA and three TA (T, TAA, and TAD) were excluded from the
experiential group due to higher AMACR expression (P < .05).
Figure W2. Correlation analysis between methylation and expression at significant loci. Primary cultured normal human prostate epithelial
cells (five) were compared to human PCa cell lines (PC3, PPC1, Du145, and LNCaP). DNA methylation was evaluated by pyrosequencing,
and gene expressionwasmeasured by RT-QPCR and normalized to β-actin (ΔCT) as described inMaterials andMethods section. Loci tested
includedCAV1, EVX1,MCF2L, and FGF1 and the two loci only found to be altered in high-grade cancer (NCR2 andWNT2). OnlyNCR2 (A) and
WNT2 (B) demonstrated significant alterations in expression between the two groups. In general, significant loci were not located in CpG-
enriched promoter regions. A Pearson coefficient was used to demonstrate significant correlations between methylation and expression
(●, human prostate epithelial cells; ▲, PCa cell lines; P < .05; experiments performed in duplicate).
